Correlation analysis of HIF-1a and CA15-3 in response to neoadjuvant chemotherapy in locally advanced breast cancer
- Conditions
- Cancerocally advanced breast cancerMalignant neoplasm of breast
- Registration Number
- ISRCTN63220723
- Lead Sponsor
- RSUP Prof. dr. R. D. Kandou Manado
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Ongoing
- Sex
- Female
- Target Recruitment
- 10
1. LABC with a histopathologically confirmed diagnosis of invasive ductal carcinoma
2. NAC regimen of cisplatin (80 mg/BSA) and gemcitabine (1,000 mg/BSA) in two cycles
3. Karnofsky Performance Status Scale >70%
1. Receiving chemotherapy with radiotherapy
2. Bilateral BC
3. Abnormal hematological parameters
4. Changes in chemotherapy regimen
5. Patients with an inherited metabolic disorder or comorbidities resulting in delayed chemotherapy
6. Acute or chronic obstructive pulmonary disease with SpO2 under 96%
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method HIF-1a and CA15-3 serum levels measured using ELISA at baseline and after receiving two cycles of NAC (Neoadjuvant chemotherapy) in a period of 5 weeks
- Secondary Outcome Measures
Name Time Method esion measurement recorded in matrix notation using a clinical caliper and evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at baseline and after receiving two cycles of NAC (Neoadjuvant chemotherapy) in a period of 5 weeks